MedTrace Logo

Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol

NCT01196130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1275

Last updated 2022-12-13

No results posted yet for this study

Summary

The goal of this clinical research study is to test for biomarkers in patients with metastatic or unresectable, locally advanced colorectal cancer. Biomarkers are chemical "markers" in the tumor tissue and/or blood that may be related to your reaction to cancer drugs.

This is an investigational study. This study's biomarker testing is for research purposes only.

Up to 1280 patients will be enrolled in this study. All will be enrolled at MD Anderson.

Conditions

Interventions

BEHAVIORAL

Cancer Symptom Questionnaire

5 minute questionnaire(s) completed at each study visit.

OTHER

Biomarker Testing

Blood draw at each study visit for biomarker and cytokine testing.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Scott Kopetz, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2022-12-09
Completion
2022-12-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196130 on ClinicalTrials.gov